1312690-85-9

Basic information

• Product Name: Methyl 6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate
• Synonyms: Methyl 6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate
• CAS NO: 1312690-85-9
• Molecular Weight: 479.579
• Mol File: 1312690-85-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Methyl 6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate(1312690-85-9)
• EPA Substance Registry System: Methyl 6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate(1312690-85-9)

Safety Data

• Hazardous Substances Data: 1312690-85-9(Hazardous Substances Data)

Upstream product

• 1312690-83-7 methyl 6-chloro-4-cyano-2-(m-tolylamino)nicotinate 
• 365996-30-1 tert-butyl ((1S,2R)-2-aminocyclohexyl)carbamate 
• 148493-37-2 2,6-dichloro-3-iodo-pyridine 
• 1312690-81-5 methyl 2,6-dichloro-4-cyanonicotinate 
• 1309866-40-7 2,6-dichloro-4-iodo-nicotinic acid methyl ester 
• 343781-55-5 2,6-dichloro-4-iodo-3-pyridinecarboxylic acid 
• 153034-86-7 2-chloro-4-iodopyridine 
• 185041-05-8 2-chloro-4-iodonicotinic acid methyl ester 
• 1289188-60-8 2-chloro-4-cyanonicotinic acid methyl ester 

Downstream Products

• 1312691-22-7 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one 
• 1312690-84-8 tert-butyl (1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate 
• 1312691-23-8 tert-butyl (1S,2R)-2-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate 
• 1312692-94-6 tert-butyl (1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate 
• 1312692-97-9 tert-butyl (1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate 
• 1312690-86-0 6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one 
• 1312692-98-0 tert-butyl (1S,2R)-2-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate 
• 1312693-12-1 tert-butyl (1S,2R)-2-(7-(3-hydroxyprop-1-ynyl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate 
• 1312693-17-6 tert-Butyl 4-(6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-7-yl)-1H-pyrazole-1-carboxylate 
• 1312692-95-7 6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one 
• 1312692-99-1 6-((1R,2S)-2-aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile 

Relevant articles and documents

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)

Spleen Tyrosine Kinase (SYK) is a non-receptor cytoplasmic tyrosine kinase that is primarily expressed in hematopoietic cells. SYK is a key mediator for a variety of inflammatory cells, including B cells, mast cells, macrophages and neutrophils and therefore, an attractive approach for treatment of both inflammatory diseases and oncology indications. Using in house co-crystal structure information, and structure-based drug design, we designed and optimized a novel series of heteroaromatic pyrrolidinone SYK inhibitors resulting in the selection of the development candidate TAK-659. TAK-659 is currently undergoing Phase I clinical trials for advanced solid tumor and lymphoma malignancies, a Phase Ib study in advanced solid tumors in combination with nivolumab, and PhIb/II trials for relapsed/refractory AML.